When did MindMaze Therapeutics announce the neurorehabilitation results, and what period did the programme cover?

MindMaze Therapeutics announced the results on March 31, 2026, and the programme covered two years. The results were presented during the American Society of Neurorehabilitation annual conference.

How did patients using MindMaze Therapeutics technology perform against standard care?

Patients using MindMaze Therapeutics technology achieved statistically significantly greater improvements than standard-of-care patients in both mobility and self-care GG scores across every site of care. The comparison used intervention patients and matched controls.

How much additional therapy did the MindMaze Therapeutics programme provide?

Patients averaged a 60% increase in additional therapy per day, totalling approximately 6.2 hours of supplemental training per patient. Participants trained on approximately 75% of their enrolled days, focusing on whole-body functional movements.

What did the MindMaze Therapeutics programme report about discharge to the community?

The MindMaze Therapeutics cohort recorded clinically meaningful and higher community discharge rates than standard care. The announcement said this represented an opportunity to return patients to their homes more quickly than standard care.

Which technologies were used in MindMaze Therapeutics’ neurorehabilitation programme?

The programme used MindMaze Therapeutics’ MindMotion Go, Izar and MindPod systems. The announcement describes these as neurotherapeutic systems providing high-dose, high-intensity, whole-body training while minimising the setup burden for therapists.

What did patients say about the MindMaze Therapeutics technology?

Approximately 77% of patients agreed that the MindMaze Therapeutics technology improved their mobility. Patients also reported increased motivation and perceived recovery benefits, and found the gamified approach more enjoyable than traditional repetitive exercises.

How does MindMaze Therapeutics explain the operational rationale for the programme?

MindMaze Therapeutics and Vibra Healthcare said the programme addressed limits on traditional therapy delivery caused by staffing constraints and patient fatigue. Vibra Healthcare Chairman and CEO Brad Hollinger said the platform increased therapy intensity without adding to the staffing burden.

What did MindMaze Therapeutics management say about the partnership’s results?

MindMaze Therapeutics CEO Zach Henderson said the results validated the company’s mission to set a new global standard for neurorehabilitation. He said the platform was not just an add-on but a vital component in maximising patient outcomes and supporting the transition from hospital to home.

What does MindMaze Therapeutics do?

MindMaze Therapeutics describes itself as a provider of scalable, precision neurotherapeutics. Its products integrate software, proprietary sensors and AI-driven data analytics to support care from the acute hospital phase through outpatient treatment and home-based therapy, addressing stroke, Parkinson’s disease and other neurological disorders.

Where do MindMaze Therapeutics shares trade and what is the ticker symbol?

MindMaze Therapeutics is identified in the announcement as listed on SIX under the ticker symbol MMTX.

What is Vibra Healthcare’s role in the MindMaze Therapeutics programme?

Vibra Healthcare implemented the programme across five of its inpatient medical rehabilitation facilities. Vibra Healthcare is a post-acute care provider focused on specialty acute care hospitals, inpatient medical rehabilitation hospitals, skilled nursing facilities and outpatient physical rehabilitation centres.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze and Vibra report neurorehabilitation results from two-year programme

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze and Vibra report neurorehabilitation results from two-year programme

Published Tuesday, 31 March 2026, 05:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Operational update
Published: Tuesday, 31 March 2026, 05:00 AM
Source announcement: eqs-news.com

Key figures
Measure	Figure
Patients	210 patients
Additional therapy per day	60%
Supplemental training per patient	approximately 6.2 hours
Patients agreeing that the technology improved their mobility	approximately 77% of patients

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics (SIX: MMTX) and Vibra Healthcare announced real-world evidence results from technology-enabled therapy in inpatient rehabilitation.

The two-year program ran across five Vibra inpatient medical rehabilitation facilities and delivered supplemental, gamified therapy to 210 patients.
MindMaze Therapeutics and Vibra Healthcare reported statistically significantly greater mobility and self-care GG-score improvements than matched controls across every site.
Patients averaged a 60% increase in additional therapy per day, totaling approximately 6.2 hours of supplemental training per patient.
Participants trained on approximately 75% of enrolled days, focusing on whole-body functional movements; community discharge rates were higher than SOC.
The program used MindMotion Go, Izar, and MindPod; approximately 77% of patients agreed the technology improved their mobility.

The results were presented during the ASNR annual conference.

Investor FAQs

MindMaze Therapeutics and Vibra Healthcare announced results from a two-year, multi-site quality improvement programme on technology-enabled, high-dose therapy in standard inpatient rehabilitation. The programme provided supplemental, gamified therapy to 210 stroke patients across five of Vibra Healthcare’s inpatient medical rehabilitation facilities.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation
Published: Tuesday, 31 March 2026, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…